Garcia-Manero, G., Przespolewski, A., Abaza, Y., Byrne, M., Fong, A. P., Jin, F., … Erba, H. P. (2022). Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part. In Blood (Vol. 140, pp. 9046–9047). American Society of Hematology. https://doi.org/10.1182/blood-2022-157606

Garcia-Manero, Guillermo, Amanda Przespolewski, Yasmin Abaza, Michael Byrne, Abraham P. Fong, Feng Jin, Alison J. Forgie, Athanasios C. Tsiatis, Shanhong Guan, and Harry P. Erba. “Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part.” In Blood, 140:9046–47. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-157606.

Garcia-Manero G, Przespolewski A, Abaza Y, Byrne M, Fong AP, Jin F, et al. Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part. In: Blood. American Society of Hematology; 2022. p. 9046–7.

Garcia-Manero, Guillermo, et al. “Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 9046–47. Crossref, doi:10.1182/blood-2022-157606.

Garcia-Manero G, Przespolewski A, Abaza Y, Byrne M, Fong AP, Jin F, Forgie AJ, Tsiatis AC, Guan S, Erba HP. Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part. Blood. American Society of Hematology; 2022. p. 9046–9047.